Articles On Imagion Biosystems (ASX:IBX)

Cancer drug developer Chimeric Therapeutics eyes minimum $5 million raising ‘The next Telix’, Clarity gets FDA go-ahead for prostate cancer trial LTR Pharma fleshes out erectile dysfunction trial results   Cancer cell therapy house Chimer...

ASX gains  as energy and mining stocks rally Arcadium Lithium surges  after Rio acquisition, while GYG reports strong Q1 Hurricane Milton lands and pushes oil prices higher   The ASX gained ground by 0.3% on Thursday and neared its recor...

Imagion raises $3 million to advance its MagSense platform MagSense is designed to revolutionise cancer diagnosis by introducing molecular imaging to MRI Strong support for the placement from a broad range of high-quality sophisticated in...

ASX fell as mining stocks dropped on China’s lack of stimulus Brent oil dipped below US$80 Big lithium stocks fall, but smaller players keep gaining after Rio Tinto’s Arcadium takeover talks   The ASX closed lower by 0.35% in a volatile...

Good morning! ASX futures were up 0.28 per cent at 8:30 am AEDT after a fairly uninspiring US session. The major US indexes ended flattish on either side of the deciding line with the S&P 500 down 0.01 per cent; the Dow up 0.04 per...

An already buoyant ASX boosted past +1.1% on happy CPI data for May. Consumer Discretionary just pipped by Real Estate, both up more than 2.1%. Stellar Resources takes line honours after hitting fresh zinc finds in Tassie.   A pleasing ba...

“I am thrilled to be leading the Imagion team and look forward to driving the company’s continued success with new solutions for cancer patients and their care teams,” said new CEO, Dr Isaac Bright.

Aussie markets are down 0.6% after the gubbermint dropped an unpopular look at the future. Gold stocks, Energy, Materials, Resources, Metals and miners are all well below the broader market. Iris Metals bucked the trend, out of the ASX dog...

The ASX closed 0.6 per cent lower on news Australia is likely to be hit with a mid-year slowdown. Investment bank UBS released data from a survey conducted over the second half of May. The figures showed a decline in the financial outloo...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The ASX is tracking negatively so far, down by 0.3 per cent at midday, with the biggest gainers being the real estate and healthcare sectors. In ASX news, Imagion Biosystems (IBX) has initiated plans to close its clinical study after ach...

Office and industrial property group, Dexus (ASX:DXS), has reduced the book value of its office and industrial properties by approximately $1 billion (6 per cent reduction) due to higher capitalization rates and discount rates as indicated...

  Sayona Mining (ASX:SYA) announced that their preliminary technical study at their NAL lithium carbonate plant study produces an NPV of A$3.2bn. Sayona’s Managing Director, Brett Lynch commented: “Significantly, NAL is set to become the on...

21 Jun 2023 - A snapshot of the stocks on the move featuring Sayona Mining (ASX:SYA), Tamboran Resources (ASX:TBN) and Imagion Biosystems (ASX:IBX).

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Imagion Biosystems (IBX) will close its MagSense HER2 imaging agent phase one clinical study after achieving its enrolment target of 13 patients IBX uses nanoparticle technology to alter how magnetic resonance imaging (MRI) and its prop...

The ASX is set to retreat after Wall Street’s momentum fades KKR agrees to buy Paypal’s BNPL portfolio in Europe Travel is set to boom as airlines line up to buy new jets   Australian shares are set to retreat at the open on Wednesday as...

At the start of a new trading week, the ASX is expected to open slightly lower, reflecting the losses incurred on Wall Street on Friday. Looking ahead, here are some ASX-listed companies to watch out for today: Lithium Power Internat...

Imagion Biosystems (IBX) deepens its annual loss by 62.8 per cent for the year ending December 31, 2022 The company incurred an operating loss of $9.8 million for the period, which it says was in line with expectations as it expanded it...

ShareCafeWebinar Recap – PFG, IBX, EMD & ATC   Catch up on the full webinar with presentations from Prime Financial Group (ASX: PFG), Imagion Biosystems (ASX: IBX), Emyria (ASX: EMD) & Altech Chemicals Webinar Recap – PFG, IBX, EMD...

ShareCafeImagion Biosystems (ASX: IBX) – Webinar Presentation Bob Proulx CEO – Imagion Biosystems are developing next-generation molecular imaging technologies that find cancer and other diseases using bio-safe magnetic nanoparticles. Imag...

Tim Boreham reports Imagion's CEO believes the oncology imaging innovator has achieved far more with its initial early-stage breast cancer study results than investors might appreciate. By Tim Boreham ASX code: IBX Share price: 2.6 cents Ma...

ShareCafeProperty sector leads ASX 0.3% lower by Peter Milios   Large property players Goodman Group (ASX:GMG), Dexus (ASX:DXS), Mirvac Group (ASX:MGR) and Charter Hall (ASX:CHC) have all suffered losses in today’s session. The index has re...

Psychedelic drugs remain the talk of an otherwise depressed market today Newmont bid for Newcrest helps drive Materials sector higher ASX benchmark limps home to be down 0.25% at the end of a gloomy Monday   It’s not exactly been a stella...

Imagion Biosystems (IBX) announces a positive outcome from an independent review of its MagSense HER2 imaging agent for breast cancer patients The review panel included expert breast radiologists, who confirmed IBX’s MagSense technology...

06 Feb 2023 - A snapshot of the stocks on the move featuring Newcrest Mining (ASX:NCM), Imagion Biosystems (ASX:IBX) and Emyria (ASX:EMD).

ShareCafeASX 0.1% lower at noon after all US indices fell over the weekend by Peter Milios   At noon, the S&P/ASX 200 is 0.1 per cent lower at 7,549.20. All sectors besides Energy and Materials are trading lower today, after the US sect...

ShareCafeStocks of the Hour: NCM, IBX, EMD                    Newcrest Mining (ASX:NCM) has confirmed that it received a conditional and non-binding indicative proposal from Newmont Corporation to acquire 100% of the issued shares of...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Imagion Biosystems (IBX) reported positive findings for its phase one HER2 breast cancer study over the December 2022 quarter The healthcare stock presented data last quarter showing its MagSense cancer detection technology is safe and c...

ShareCafeLithium slammed by GS, NSW close to energy deal with Federal Government: ASX closes 0.6% lower by Peter Milios   Goldman Sachs have extended their bearish views on lithium, believing that the prices are expected to decline from the...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Cancer detection technology developer Imagion Biosystems (ASX: IBX) has reported a maiden set of results relating to exploratory endpoints for its phase 1 MagSense HER...

ShareCafeLithium stocks under pressure following Goldman’s comments: ASX down 0.47% at noon by Lauren Hayes   The Australian market is still unnerved over concerns about a possible US recession. Energy is weighing down the benchmark over fe...

ShareCafeStocks of the Hour: CZN, SOP, IBX                    Corazon Mining (ASX:CZN) has discovered spodumene pegmatites at their Miriam Project in Western Australia. The company has found widespread indicators of pegmatite througho...

08 Dec 2022 - A snapshot of the stocks on the move featuring Corazon Mining (ASX:CZN), Synertec Corporation (ASX:SOP) and Imagion Biosystems (ASX:IBX).

Imagion presents positive data at world leading symposium Osteopore expands in Southeast Asia Microba expands into Italy and Portugal   Imagion speaks at world-leading breast cancer symposium Imagion Biosystems (ASX:IBX) is set to rise ov...

08 Dec 2022 - A snapshot of the stocks on the move featuring Corazon Mining (ASX:CZN), Synertec Corporation (ASX:SOP) and Imagion Biosystems (ASX:IBX).

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Imagion Biosystems (IBX) reports evidence in human patients that its MagSense cancer detection tech could improve the standard of care for cancer patientsNew trial data shows the IBX MagSense tech, when combined with conventional MRI scans,...

The ASX is set to fall for a third consecutive day Tech stocks dragged Wall Street down overnight, as talks of a US recession continue to build up Most commodity prices slip on demand concern   Local shares are set to fall for a third con...

ASX-listed Imagion Biosystems (IBX) is bringing groundbreaking nanotechnology to the world of healthcareThe nanoparticles industry, while already thriving, is pegged by market researcher Emergen to top US$33.7 billion (A$53.5 billion) in va...

Imagion Biosystems (IBX) progressed research and development activities for its MagSense cancer detection technology in the September quarterThe healthcare company continued enrolling patients into the HER2 breast cancer phase one study whi...

Robert Proulx of Imagion Biosystems speaks at the Switzer Small and Micro Cap Investor Strategy Day September 2022.

Imagion Biosystems (IBX) is set to present its prostate cancer research at the 2022 World Molecular Imaging Congress in Miami, FloridaThe research data relates to the company’s prostate cancer imaging agent, MagSenseThe data shows evidence...

Imagion Biosystems (IBX) increases its operational spending during the half year as it aims to expand its development pipeline Over the course of six months, the company lifted operating cash outflows to $4.8 million and increased its net...

Highlights Wellnex Life has signed a supply agreement with GSK CTS for its innovative soft gel liquid paracetamol in the ANZ market. The product will be supplied under GSK’s pain relief brand. Under the agreement, WNX gets the privile...

  Highlights Imagion Biosystems marks significant progress in its first-in-human study for the MagSense® HER2 breast cancer imaging agent. The interim results for the first five patients dosed show that the imaging agent is safe and w...

The Emerging Companies Index (XEC) climbed more than 2% higher on Thursday, before closing at 1.9%, while its benchmark colleague – the upmarket ASX 200 followed Wall Street’s ascendence, trading up a shade over 1% after the Fed lifted inte...

The share market sealed its best two-day advance in six weeks as unemployment hit a 14-year low and Wall Street welcomed clarity on this year’s rates outlook.    The S&P/ASX 200 climbed 72 points or 1 per cent to its highest close si...

Highlights The Australian market opened on a cheerful note today tracking Wall Street’s positive close amid the US Fed pulled the trigger on rate hike. The ASX Small Ordinaries index has jumped to its highest level for this month. IBX...